Steroid Treatment Effect in Pulmonary Sarcoidosis
- Conditions
- sarcoidosis10024967
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 50
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Patients with stage II/III (based on a chest X-ray or equivalent on a CT-scan) sarcoidosis (established using the criteria of the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG));
- A FVC * 80% of predicted AND/OR an absolute decline of *10% predicted FVC within 12 months;
- A pulmonary indication for prednisolone treatment (determined by the treating physician and conform current clinical guidelines) ;
- Written informed consent;
- Age > 18.
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Previous immunosuppressive treatment for sarcoidosis (e.g. prednisone, methotrexate (MTX), Infliximab);
- Use of systemic immunosuppressive therapy within the previous 3 months for another disease then sarcoidosis;
- Contra-indication for steroids;
- Other conditions which could influence pulmonary function, such as:
o Concurrent chronic obstructive pulmonary disorder (COPD);
o Concurrent active asthma (according to GINA guidelines);
o Fibrotic lung disease;
o Pregnancy;
o Morbide obesitas (BMI > 30);
- Pulmonary malignancies.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1. Repeated measurements of the FVC and prednisone dose used</p><br>
- Secondary Outcome Measures
Name Time Method